Development and testing of a novel biosynthesized XCell for treating chronic wounds

Biosynthesized cellulose is produced by the bacteria, Acetobacter xylinum, and possesses unique properties not present in other biomaterials. The material is formed during fermentation having a multi-layered structure composed of fine, nonwoven, cellulose hydrophilic fibers. This structure allows biosynthesized cellulose to have a high-fluid capacity, superior strength, and biocompatibility, which makes it suitable for topical and implantable biomedical applications. Initial product development of biosynthesized cellulose has focused on advanced wound-care applications. The product, XCell (Xylos Corporation, Langhorne, PA, USA), has been bioengineered to have the ability to both donate and absorb moisture, depending on the wound environment. Comparative bench testing has shown that XCell is the only wound dressing with this unique dual-fluid-handling capability. The product has been studied thoroughly using animal models and proved to be safe and biocompatible. Human clinical testing has demonstrated its effectiveness in providing a moist environment, essential to treating hard-to-heal chronic wounds. The major clinical benefits of the product include: 1) help in removal of non-viable tissue and promotion of autolytic debridement, which results in increased granulation tissue; 2) cleansing of wound margins that leads to epithelial migration and reduction of wound size; and 3) healing of various types of chronic wounds.